The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

Viagra-Like Pill Slows Alzheimer Decline by 31%

By The Daily Byte ·21 Nov 2026 ·4 min read
Distressed older man holding his head while a carer places a hand on his shoulder

A once-daily pill from the same drug family as Viagra slowed the decline of people with early Alzheimer's disease by 31% in a major trial, researchers have reported, although the benefit was seen only in patients who were not already taking other dementia medicines.

The drug, AR1001, was tested in the global Phase 3 POLARIS-AD trial involving 1,535 people with early Alzheimer's disease in 13 countries, including the UK. The findings were presented on 16 November at the Clinical Trials on Alzheimer's Disease conference in Boston by its developer, South Korean company AriBio.

Participants were randomly assigned to receive 30mg of AR1001 or a placebo every day for 52 weeks. In a prespecified subgroup of 604 people who were not taking other Alzheimer's medicines at the start of the trial, the rate of decline was 31% slower than in the placebo group, a statistically significant result. The company reported the difference on the Clinical Dementia Rating-Sum of Boxes scale, which measures thinking and daily functioning, as 0.44 points.

Two different results from one trial

The picture was very different across the trial as a whole. When all 1,535 participants were counted together, including those already taking medicines such as cholinesterase inhibitors or memantine, the difference was only 0.11 points and was not statistically significant. In other words, the trial did not show a benefit for the full group, and the reported 31% slowing applies to the subgroup alone.

That split is the central question now facing the drug. AriBio had specified in advance that it would judge the results in both ways, in everyone and in people not taking other dementia medicines, and it says the subgroup finding met its threshold for statistical significance. But researchers not involved in the trial say the result needs confirmation, and AriBio has not announced a date for a regulatory filing. The company said it plans to discuss the results with the US Food and Drug Administration.

Side effects were generally mild to moderate. Adverse events were reported by 69% of participants given AR1001 and 66.4% of those given a placebo, while serious events occurred in about 10% of each group. Treatment was stopped because of side effects by 5.2% of those taking AR1001, compared with 1.7% on placebo, with dizziness, diarrhoea and falls more common among those given the drug.

How AR1001 differs from Viagra

AR1001, also known as mirodenafil, is a phosphodiesterase-5 (PDE5) inhibitor, the same drug class as Viagra, whose active ingredient is sildenafil. Mirodenafil was developed for erectile dysfunction and is sold as Mvix in South Korea. PDE5 inhibitors relax blood vessels, and AriBio is studying whether the drug may also affect Alzheimer's disease by improving blood flow to the brain and stimulating signalling pathways inside brain cells involved in learning and memory.

The company also reported biomarker changes in the subgroup, including raised levels of cGMP, a signalling molecule, in spinal fluid, and lower levels of p-tau217, a marker associated with Alzheimer's. If approved, AR1001 would be an oral treatment, unlike some existing disease-modifying treatments that target amyloid, a protein associated with Alzheimer's, and are given by injection or infusion. The trial did not compare AR1001 directly with those treatments.

Experts urge caution

Dr Richard Oakley, associate director of research and innovation at the Alzheimer's Society, called the results "an exciting sign" that a new treatment addressing the underlying causes of the disease could be on the horizon. Professor Tara Spires-Jones of the University of Edinburgh Medical School said the study "looks very promising". Dr Sharon Sha of Stanford University, the trial's principal investigator, said the secondary and biomarker findings warranted further evaluation alongside the overall result.

All three stressed the limits of the evidence. Oakley said further research was needed to understand why no effect was seen when the drug was taken alongside existing treatments, and that rigorous evaluation by the scientific community and regulators would be required before it could be prescribed. He also cautioned that people should not take Viagra to treat Alzheimer's: AR1001 is being developed specifically for the disease and is not approved for that use. The findings do not show that Viagra or other PDE5 drugs treat Alzheimer's.

Alzheimer's is the most common form of dementia, and there is currently no cure. The company estimated that after a year, people on the drug in the subgroup were roughly where the placebo group had been about three and a half months earlier. Whether that difference can be repeated in a further trial, and whether regulators will accept the subgroup evidence, will decide if the pill ever reaches patients.